Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Jennifer Cruickshank"'
Autor:
Jenna E. van Leeuwen, Wail Ba-Alawi, Emily Branchard, Jennifer Cruickshank, Wiebke Schormann, Joseph Longo, Jennifer Silvester, Peter L. Gross, David W. Andrews, David W. Cescon, Benjamin Haibe-Kains, Linda Z. Penn, Deena M. A. Gendoo
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
Statins are promising for breast cancer therapy; dipyridamole can potentiate their effects, but is contraindicated in some cases. Here, the authors develop a pharmacogenomics pipeline to predict other compounds that potentiate statins, and validate t
Externí odkaz:
https://doaj.org/article/f57984f909454f0787ee786ab65589d9
Autor:
Elisabeth Prince, Jennifer Cruickshank, Wail Ba-Alawi, Kelsey Hodgson, Jillian Haight, Chantal Tobin, Andrew Wakeman, Alona Avoulov, Valentina Topolskaia, Mitchell J. Elliott, Alison P. McGuigan, Hal K. Berman, Benjamin Haibe-Kains, David W. Cescon, Eugenia Kumacheva
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
Patient-derived tumour organoids are important preclinical models but suffer from variability from the use of basement-membrane extract and cell contamination. Here, the authors report on the development of mimetic nanofibrilar hydrogel which support
Externí odkaz:
https://doaj.org/article/dda5710243f944a48c6092025f6d253a
Autor:
Armen Parsyan, Jennifer Cruickshank, Kelsey Hodgson, Drew Wakeham, Sierra Pellizzari, Vasudeva Bhat, David W. Cescon
Publikováno v:
Breast, Vol 58, Iss , Pp 6-9 (2021)
Development of novel multimodality radiotherapy treatments in metastatic breast cancer, especially in the most aggressive triple negative (TNBC) subtype, is of significant clinical interest. Here we show that a novel inhibitor of Polo-Like Kinase 4 (
Externí odkaz:
https://doaj.org/article/d129a108948546669208676583fd01f1
Autor:
Qin Wu, Wail ba-alawi, Genevieve Deblois, Jennifer Cruickshank, Shili Duan, Evelyne Lima-Fernandes, Jillian Haight, Seyed Ali Madani Tonekaboni, Anne-Marie Fortier, Hellen Kuasne, Trevor D. McKee, Hassan Mahmoud, Michelle Kushida, Sarina Cameron, Nergiz Dogan-Artun, WenJun Chen, Yan Nie, Lan Xin Zhang, Ravi N. Vellanki, Stanley Zhou, Panagiotis Prinos, Bradly G. Wouters, Peter B. Dirks, Susan J. Done, Morag Park, David W. Cescon, Benjamin Haibe-Kains, Mathieu Lupien, Cheryl H. Arrowsmith
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Triple negative breast cancer is a deadly form of breast cancer with limited therapeutic options. Here the authors show the efficacy of GLUT1 pharmacological inhibition against a subset of tumors expressing RB1, thereby identifying RB1 protein level
Externí odkaz:
https://doaj.org/article/130018a3112a40a29ff505012c3352a4
Autor:
Alexander E.G. Baker, Laura C. Bahlmann, Chang Xue, Yung Hsiang (John) Lu, Allysia A. Chin, Jennifer Cruickshank, David W. Cescon, Molly S. Shoichet
Publikováno v:
Materials Today. 56:96-113
Autor:
Salvador Mejia-Guerrero, Thomas Kislinger, Vladimir Ignatchenko, Lydia Y Liu, Meinusha Govindarajan, Ankit Sinha, Andrew Macklin, Jennifer Cruickshank, Hal K. Berman, Amanda Khoo, Laura Kuhlmann
Publikováno v:
Cancer Research. 81:PS18-31
Triple negative breast cancer (TNBC) stands out due to its aggressive course and high metastatic rates. No consistent protein biomarker has been described for TNBC, resulting in a scarcity of adjuvant therapies for the afflicted patients. Hence, ther
Autor:
Isabel, Soria-Bretones, Kelsie L, Thu, Jennifer, Silvester, Jennifer, Cruickshank, Samah, El Ghamrasni, Wail, Ba-Alawi, Graham C, Fletcher, Reza, Kiarash, Mitchell J, Elliott, Jordan J, Chalmers, Andrea C, Elia, Albert, Cheng, April A N, Rose, Mark R, Bray, Benjamin, Haibe-Kains, Tak W, Mak, David W, Cescon
Publikováno v:
Science advances. 8(36)
Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) are standard first-line treatments for metastatic ER
Autor:
Laura Kuhlmann, Meinusha Govindarajan, Salvador Mejia-Guerrero, Vladimir Ignatchenko, Lydia Y. Liu, Barbara T. Grünwald, Jennifer Cruickshank, Hal Berman, Rama Khokha, Thomas Kislinger
Publikováno v:
Journal of proteome research. 21(9)
Driven by the lack of targeted therapies, triple-negative breast cancers (TNBCs) have the worst overall survival of all breast cancer subtypes. Considering that cell surface proteins are favorable drug targets and are predominantly glycosylated, glyc
Autor:
Ankit Sinha, Hyeyeon Kim, Jennifer Cruickshank, Mina Alam, Marianne Koritzinsky, Mar Garcia-Valero, Curtis W McCloskey, Rama Khokha, Ravi N. Vellanki, Mathepan Mahendralingam, Luis Palomero, Vid Stambolic, Alison E. Casey, Ronak Shetty, Aaron D. Schimmer, Pirashaanthy Tharmapalan, Miquel Angel Pujana, Davide Pellacani, Vladimir Ignatchenko, Connie J. Eaves, Thomas Kislinger, Kazeera Aliar, Hal K. Berman
Publikováno v:
Nature Metabolism. 3:665-681
Cancer metabolism adapts the metabolic network of its tissue of origin. However, breast cancer is not a disease of a single origin. Multiple epithelial populations serve as the culprit cell of origin for specific breast cancer subtypes, yet our knowl
Autor:
Drew Wakeham, David W. Cescon, Kelsey Hodgson, Armen Parsyan, Sierra Pellizzari, Vasudeva Bhat, Jennifer Cruickshank
Publikováno v:
The Breast : Official Journal of the European Society of Mastology
Breast, Vol 58, Iss, Pp 6-9 (2021)
Breast, Vol 58, Iss, Pp 6-9 (2021)
Development of novel multimodality radiotherapy treatments in metastatic breast cancer, especially in the most aggressive triple negative (TNBC) subtype, is of significant clinical interest. Here we show that a novel inhibitor of Polo-Like Kinase 4 (